Heinz H Coenen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4220182/publications.pdf

Version: 2024-02-01

137 papers	7,101 citations	66343 42 h-index	60623 81 g-index
140 all docs	140 docs citations	140 times ranked	6307 citing authors

#	Article	IF	Citations
1	Current trends in the use of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) in neurooncology. Nuclear Medicine and Biology, 2021, 92, 78-84.	0.6	30
2	Expanding PET-applications in life sciences with positron-emitters beyond fluorine-18. Nuclear Medicine and Biology, 2021, 92, 241-269.	0.6	19
3	Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 7.	3.9	9
4	Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. Clinical and Translational Imaging, 2019, 7, 61-63.	2.1	3
5	Baeyerâ€Villiger oxidation tuned to chemoselective conversion of nonâ€activated [¹⁸F]fluorobenzaldehydes to [¹⁸F]fluorophenols. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 380-392.	1.0	2
6	Status of the â€˜consensus nomenclature rules in radiopharmaceutical sciencesâ€™ initiative. Nuclear Medicine and Biology, 2019, 71, 19-22.	0.6	7
7	Treatment-Related Uptake of O-(2-¹⁸F-Fluoroethyl)-l-Tyrosine and l-[Methyl-³H]-Methionine After Tumor Resection in Rat Glioma Models. Journal of Nuclear Medicine, 2019, 60, 1373-1379.	5.0	7
8	^{52g/55}Mn-Labelled CDTA-based trimeric complexes as novel bimodal PET/MR probes with high relaxivity. Dalton Transactions, 2019, 48, 3003-3008.	3.3	6
9	Cis-4-[18F]fluoro-D-proline detects neurodegeneration in patients with akinetic-rigid parkinsonism. Nuclear Medicine Communications, 2019, 40, 383-387.	1.1	4
10	Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. Annals of Nuclear Medicine, 2018, 32, 236-238.	2.2	23
11	18F-labelling innovations and their potential for clinical application. Clinical and Translational Imaging, 2018, 6, 169-193.	2.1	37
12	Cross section measurements of ⁷⁵As(Î±,xn)^{76,77,78}Br and ⁷⁵As(Î±,x)⁷⁴As nuclear reactions using the monitor radionuclides ⁶⁷Ga and ⁶⁶Ga for beam evaluation. Radiochimica Acta, 2017, 105, 431-439.	1.2	7
13	Efficient synthesis of [¹⁸F]FPyME: A new approach for the preparation of maleimideâ€containing prosthetic groups for the conjugation with thiols. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 87-92.	1.0	6
14	Consensus nomenclature rules for radiopharmaceutical chemistry â€” Setting the record straight. Nuclear Medicine and Biology, 2017, 55, v-xi.	0.6	162
15	Novel CDTA-based, Bifunctional Chelators for Stable and Inert Mn^{II} Complexation: Synthesis and Physicochemical Characterization. Inorganic Chemistry, 2017, 56, 7746-7760.	4.0	36
16	New potent A1 adenosine receptor radioligands for positron emission tomography. Nuclear Medicine and Biology, 2017, 44, 69-77.	0.6	12
17	Circadian variation of metabotropic glutamate receptor 5 availability in the rat brain. Journal of Sleep Research, 2016, 25, 754-761.	3.2	47
18	Reproducibility of O-(2-18F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1115-1123.	6.4	15

#	Article	IF	Citations
19	Radiolabelling with isotopic mixtures of^{52g/55}Mn(<scp>ii</scp>) as a straight route to stable manganese complexes for bimodal PET/MR imaging. Dalton Transactions, 2016, 45, 1315-1321.	3.3	22
20	Noâ€carrierâ€added labeling of the neuroprotective Ebselen with seleniumâ€73 and seleniumâ€75. Journal of Labelled Compounds and Radiopharmaceuticals, 2015, 58, 141-145.	1.0	4
21	A threeâ€step radiosynthesis of 6â€[¹⁸â€‰F]fluoroâ€Lâ€metaâ€tyrosine starting with [¹⁸â€‰F]fluoride. Journal of Labelled Compounds and Radiopharmaceuticals, 2015, 58, 133-140.	1.0	7
22	4-[18F]Fluorophenylpiperazines by Improved Hartwig-Buchwald N-Arylation of 4-[18F]fluoroiodobenzene, Formed via Hypervalent Î»3-Iodane Precursors: Application to Build-Up of the Dopamine D4 Ligand [18F]FAUC 316. Molecules, 2015, 20, 470-486.	3.8	21
23	Authentically radiolabelled Mn(II) complexes as bimodal PET/MR tracers. EJNMMI Physics, 2015, 2, A85.	2.7	3
24	Optimized separation procedure for production of no-carrier-added radiomanganese for positron emission tomography. Radiochimica Acta, 2015, 103, 893-899.	1.2	16
25	Uptake and tracer kinetics of O-(2-18F-fluoroethyl)-l-tyrosine in meningiomas: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 459-467.	6.4	24
26	Stereoselective radiosynthesis of l- and d-3-[18F]fluoro-Î±-methyltyrosine. Journal of Fluorine Chemistry, 2015, 178, 202-207.	1.7	7
27	The Usefulness of Dynamic O-(2-¹⁸F-Fluoroethyl)-l-Tyrosine PET in the Clinical Evaluation of Brain Tumors in Children and Adolescents. Journal of Nuclear Medicine, 2015, 56, 88-92.	5.0	64
28	Radiosynthesis of 4-[18 F]fluoro- l -tryptophan by isotopic exchange on carbonyl-activated precursors. Bioorganic and Medicinal Chemistry, 2015, 23, 5856-5869.	3.0	14
29	Comparison of Cerebral Blood Flow Acquired by Simultaneous [¹⁵O]Water Positron Emission Tomography and Arterial Spin Labeling Magnetic Resonance Imaging. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1373-1380.	4.3	118
30	Relationship of regional cerebral blood flow and kinetic behaviour of O-(2-18F-fluoroethyl)-L-tyrosine uptake in cerebral gliomas. Nuclear Medicine Communications, 2014, 35, 245-251.	1.1	18
31	Optimizing the transfer of [18F]fluoride from aqueous to organic solvents by electrodeposition using carbon electrodes. Applied Radiation and Isotopes, 2014, 91, 1-7.	1.5	5
32	Oxytocin enhances attractiveness of unfamiliar female faces independent of the dopamine reward system. Psychoneuroendocrinology, 2014, 39, 74-87.	2.7	86
33	Iodonium ylides for one-step, no-carrier-added radiofluorination of electron rich arenes, exemplified with 4-(([18F]fluorophenoxy)-phenylmethyl)piperidine NET and SERT ligands. RSC Advances, 2014, 4, 17293-17299.	3.6	70
34	Image derived input function applied in CBF Studies with [15O]water PET in an integrated MR-PET. EJNMMI Physics, 2014, 1, A30.	2.7	1
35	Comparison of ¹⁸F-FET PET and Perfusion-Weighted MR Imaging: A PET/MR Imaging Hybrid Study in Patients with Brain Tumors. Journal of Nuclear Medicine, 2014, 55, 540-545.	5.0	115
36	Histogram analysis reveals a better delineation of tumor volume from background in 18F-FET PET compared to CBV maps in a hybrid PETâ€“MR studie in gliomas. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2014, 734, 175-178.	1.6	2

#	Article	IF	Citations
37	Effects of Magnetic Fields of up to 9.4 T on Resolution and Contrast of PET Images as Measured with an MR-BrainPET. PLoS ONE, 2014, 9, e95250.	2.5	28
38	Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-l-tyrosine PET in comparison to MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 22-33.	6.4	158
39	Uptake of O-(2-[18F]fluoroethyl)-L-tyrosine in reactive astrocytosis in the vicinity of cerebral gliomas. Nuclear Medicine and Biology, 2013, 40, 795-800.	0.6	24
40	Bis(4-benzyloxyphenyl)iodonium salts as effective precursors for the no-carrier-added radiosynthesis of 4-[18F]fluorophenol. Applied Radiation and Isotopes, 2013, 82, 264-267.	1.5	14
41	Diagnostic Performance of ¹⁸F-FET PET in Newly Diagnosed Cerebral Lesions Suggestive of Glioma. Journal of Nuclear Medicine, 2013, 54, 229-235.	5.0	167
42	Labeling of benzodioxin piperazines with fluorineâ€18 as prospective radioligands for selective imaging of dopamine D₄ receptors. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 609-618.	1.0	7
43	Methods for ¹¹Câ€and ¹⁸Fâ€labelling of amino acids and derivatives for positron emission tomography imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 225-236.	1.0	39
44	Role of O-(2-¹⁸F-Fluoroethyl)-l-Tyrosine PET as a Diagnostic Tool for Detection of Malignant Progression in Patients with Low-Grade Glioma. Journal of Nuclear Medicine, 2013, 54, 2046-2054.	5.0	108
45	Monitoring of Radiochemotherapy in Patients with Glioblastoma Using O -(2-[¹⁸) Tj ETQq1 1 0.784314 rgBT /Ov Imaging, 2013, 12, 7290.2013.00056.	1.4	19
46	Assessment of Treatment Response in Patients with Glioblastoma Using O-(2-¹⁸F-Fluoroethyl)-l-Tyrosine PET in Comparison to MRI. Journal of Nuclear Medicine, 2012, 53, 1048-1057.	5.0	184
47	Radiochemical separation of 76,77Br and 66,67Ga from irradiated ZnSe targets using anion-exchange chromatography. Radiochimica Acta, 2012, 100, 785-792.	1.2	4
48	Carrierâ€effect on palladiumâ€catalyzed, nucleophilic ¹⁸Fâ€fluorination of aryl triflates. Journal of Labelled Compounds and Radiopharmaceuticals, 2012, 55, 450-453.	1.0	19
49	Role of O-(2-¹⁸F-Fluoroethyl)-l-Tyrosine PET for Differentiation of Local Recurrent Brain Metastasis from Radiation Necrosis. Journal of Nuclear Medicine, 2012, 53, 1367-1374.	5.0	171
50	Convenient preparation of (4-iodophenyl)aryliodonium salts. Tetrahedron, 2012, 68, 4112-4116.	1.9	11
51	Enantiospecific synthesis of 2-[18F]fluoro-l-phenylalanine and 2-[18F]fluoro-l-tyrosine by isotopic exchange. Organic and Biomolecular Chemistry, 2011, 9, 765-769.	2.8	21
52	Evaluation of18F-Labeled Benzodioxine Piperazine-Based Dopamine D4Receptor Ligands: Lipophilicity as a Determinate of Nonspecific Binding. Journal of Medicinal Chemistry, 2011, 54, 8343-8352.	6.4	26
53	Prognostic impact of postoperative, pre-irradiation 18F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiotherapy and Oncology, 2011, 99, 218-224.	0.6	82
54	Synthesis of No-Carrier-Added 4-[18F]Fluorophenol from 4-Benzyloxyphenyl-(2-thienyl)iodonium Bromide. Molecules, 2011, 16, 7621-7626.	3.8	17

#	Article	IF	Citations
55	Prognostic Value of Early [18F]Fluoroethyltyrosine Positron Emission Tomography After Radiochemotherapy in Glioblastoma Multiforme. International Journal of Radiation Oncology Biology Physics, 2011, 80, 176-184.	0.8	132
56	Small scale production of high purity 193mPt by the 192Os(Î±,ß™3n)-process. Radiochimica Acta, 2011, 99, 131-135.	1.2	10
57	Efficient synthesis of fluorobenzyloxoimidazolidinone derivatives: precursors for the radiosynthesis of [18F]fluorophenylamino acids. Tetrahedron, 2010, 66, 9996-10001.	1.9	4
58	New cross section measurements for the production of the Auger electron emitters⁷⁷Br and^{80m}Br. Radiochimica Acta, 2010, 98, 749-755.	1.2	14
59	Comparison of O-(2-¹⁸F-Fluoroethyl)-l-Tyrosine and l-³H-Methionine Uptake in Cerebral Hematomas. Journal of Nuclear Medicine, 2010, 51, 790-797.	5.0	33
60	Synthesis, radiofluorination and first evaluation of [18F]fluorophenylsulfonyl- and [18F]fluorophenylsulfinyl-piperidines as serotonin 5-HT2A receptor antagonists for PET. Nuclear Medicine and Biology, 2010, 37, 605-614.	0.6	4
61	Nucleophilic 18F-Fluorination of Complex Molecules in Activated Carbocyclic Aromatic Position. Current Radiopharmaceuticals, 2010, 3, 109-126.	0.8	15
62	No-Carrier-Added [18F]Fluorobenzene Derivatives as Intermediates for Built-up Radiosyntheses. Current Radiopharmaceuticals, 2010, 3, 127-160.	0.8	16
63	Direct Nucleophilic 18F-Fluorination of Electron Rich Arenes: Present Limits of No-Carrier-Added Reactions. Current Radiopharmaceuticals, 2010, 3, 163-173.	0.8	21
64	New cross section measurements for production of the positron emitters 75Br and 76Br via intermediate energy proton induced reactions. Radiochimica Acta, 2009, 97, .	1.2	17
65	Three-Step, â€œOne-Potâ€•Radiosynthesis of 6-Fluoro-3,4-Dihydroxy-l-Phenylalanine by Isotopic Exchange. Journal of Nuclear Medicine, 2009, 50, 1724-1729.	5.0	63
66	The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma. Physics in Medicine and Biology, 2009, 54, 5525-5539.	3.0	46
67	Synthesis, radiofluorination and first evaluation of (Â±)â€[¹⁸F]MDL 100907 as serotonin 5â€HT_{2A} receptor antagonist for PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2009, 52, 6-12.	1.0	23
68	Synthesis, labelling and first evaluation of [¹⁸F]R91150 as a serotonin 5â€HT_{2A} receptor antagonist for PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2009, 52, 13-22.	1.0	18
69	Combined MRIâ€“PET dissects dynamic changes in plant structures and functions. Plant Journal, 2009, 59, 634-644.	5.7	268
70	Comparison of 18F-FET and 18F-FDG PET in brain tumors. Nuclear Medicine and Biology, 2009, 36, 779-787.	0.6	177
71	Cerebral A1 adenosine receptors (A1AR) in liver cirrhosis. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 589-597.	6.4	28
72	Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2144-2151.	6.4	78

#	Article	IF	Citations
73	cis-4-[18F]-Fluoro-l-proline fails to detect peripheral tumors in humans. Nuclear Medicine and Biology, 2008, 35, 895-900.	0.6	7
74	Mesolimbic Functional Magnetic Resonance Imaging Activations during Reward Anticipation Correlate with Reward-Related Ventral Striatal Dopamine Release. Journal of Neuroscience, 2008, 28, 14311-14319.	3.6	426
75	Multimodal Imaging of Neural Progenitor Cell Fate in Rodents. Molecular Imaging, 2008, 7, 7290.2008.0010.	1.4	49
76	Detection of Secondary Thalamic Degeneration After Cortical Infarction Using cis-4-18F-Fluoro-D-Proline. Journal of Nuclear Medicine, 2007, 48, 1482-1491.	5.0	19
77	Sleep Deprivation Increases A1 Adenosine Receptor Binding in the Human Brain: A Positron Emission Tomography Study. Journal of Neuroscience, 2007, 27, 2410-2415.	3.6	169
78	Prognostic Value of O-(2-18F-Fluoroethyl)-L-Tyrosine PET and MRI in Low-Grade Glioma. Journal of Nuclear Medicine, 2007, 48, 519-527.	5.0	171
79	Positron emission intensities in the decay of 64Cu, 76Br and 124I. Radiochimica Acta, 2007, 95, 67-73.	1.2	74
80	Nuclear data for production of 88Y, 140Nd, 153Sm and 169Yb via novel routes. Radiochimica Acta, 2007, 95, 313-317.	1.2	20
81	New 2Î±-tropane amides as potential PET ligands for the dopamine transporter. Nuclear Medicine and Biology, 2007, 34, 531-539.	0.6	5
82	Nucleophilic18F-Fluorination of Heteroaromatic Iodonium Salts with No-Carrier-Added [18F]Fluoride. Journal of the American Chemical Society, 2007, 129, 8018-8025.	13.7	194
83	N-2-(4-N-(4-[18F]Fluorobenzamido)phenyl)-propyl-2-propanesulphonamide: synthesis and radiofluorination of a putative AMPA receptor ligand. Journal of Labelled Compounds and Radiopharmaceuticals, 2007, 50, 1169-1175.	1.0	7
84	[18F]Fluorophenyl organometallics as intermediates of no-carrier-added 18F-fluoroarylation reactions. Journal of Organometallic Chemistry, 2007, 692, 4084-4092.	1.8	5
85	O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nuclear Medicine and Biology, 2006, 33, 287-294.	0.6	317
86	Differential uptake of [18F]FET and [3H]l-methionine in focal cortical ischemia. Nuclear Medicine and Biology, 2006, 33, 1029-1035.	0.6	55
87	Synthesis andÂevaluation ofÂ7-amino-2-(2(3)-furyl)-5-phenylethylamino-oxazolo[5,4-d]pyrimidines asÂpotential A2A adenosine receptor antagonists forÂpositron emission tomography (PET). European Journal of Medicinal Chemistry, 2006, 41, 7-15.	5.5	33
88	4-[18F]fluorophenyl ureas via carbamate-4-nitrophenyl esters and 4-[18F]fluoroaniline. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 1037-1050.	1.0	11
89	METABOLISM OF THE A1 ADENOSINE RECEPTOR POSITRON EMISSION TOMOGRAPHY LIGAND [18F]8-CYCLOPENTYL-3-(3-FLUOROPROPYL)-1-PROPYLXANTHINE ([18F]CPFPX) IN RODENTS AND HUMANS. Drug Metabolism and Disposition, 2006, 34, 570-576.	3.3	28
90	18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer. Journal of Nuclear Medicine, 2006, 47, 256-61.	5.0	67

#	Article	IF	Citations
91	Preferred Stereoselective Transport of the D-isomer of cis-4-[18F]fluoro-proline at the Bloodâ€“Brain Barrier. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 607-616.	4.3	36
92	Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia. Anatomy and Embryology, 2005, 210, 519-523.	1.5	39
93	O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain, 2005, 128, 678-687.	7.6	537
94	Experimental measurements and nuclear model calculations on the excitation functions of natCe(3He,) Tj ETQq0 0 0 rgBT /Overlock 10 140Nd. Radiochimica Acta, 2005, 93, 553-560.	1.2	29
95	Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET: an equilibrium approach. NeuroImage, 2005, 24, 1192-1204.	4.2	25
96	Preferred stereoselective brain uptake of d-serine â€" a modulator of glutamatergic neurotransmission. Nuclear Medicine and Biology, 2005, 32, 793-797.	0.6	44
97	PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in peripheral tumors: first clinical results. Journal of Nuclear Medicine, 2005, 46, 411-6.	5.0	75
98	18F-CPFPX PET identifies changes in cerebral A1 adenosine receptor density caused by glioma invasion. Journal of Nuclear Medicine, 2005, 46, 450-4.	5.0	32
99	Enhanced production possibility of the therapeutic radionuclides 64Cu, 67Cu and 89Sr via (n,p) reactions induced by fast spectral neutrons. Radiochimica Acta, 2004, 92, 183-186.	1.2	40
100	In Memoriam Gerhard L. StÃ¶cklin. Radiochimica Acta, 2004, 92, 189-191.	1.2	0
101	Excitation functions of deuteron induced nuclear reactions on enriched 78Kr with particular relevance to the production of 76Br. Radiochimica Acta, 2004, 92, 203-207.	1.2	11
102	Quantification of Cerebral A1 Adenosine Receptors in Humans using [18F]CPFPX and PET. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 323-333.	4.3	33
103	Application of n.c.a. 4-[18F]fluorophenol in diaryl ether syntheses of 2-(4-[18F]fluorophenoxy)-benzylamines. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 443-455.	1.0	12
104	First no-carrier-added radioselenation of an adenosine-A1 receptor ligand. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 415-427.	1.0	8
105	Comparison of pathways to the versatile synthon of no-carrier-added 1-bromo-4-[18F]fluorobenzene. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 429-441.	1.0	60
106	Obituary of Prof. StÃ¶cklin, Sydney, August 10, 2003. Nuclear Medicine and Biology, 2004, 31, 531.	0.6	0
107	Imaging of gliomas with Cis-4-[18F]fluoro-L-proline. Nuclear Medicine and Biology, 2004, 31, 67-75.	0.6	17
108	Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors. Journal of Nuclear Medicine, 2004, 45, 374-81.	5.0	65

#	Article	IF	Citations
109	Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-l-tyrosine. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 519-524.	6.4	97
110	Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Annals of Neurology, 2003, 54, 479-487.	5.3	235
111	In vivo imaging of adenosine A1 receptors in the human brain with [18F]CPFPX and positron emission tomography. NeuroImage, 2003, 19, 1760-1769.	4.2	84
112	No-carrier-added synthesis of aliphatic and aromatic radioselenoethers via selenocyanates. Nuclear Medicine and Biology, 2003, 30, 361-367.	0.6	4
113	Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nuclear Medicine and Biology, 2003, 30, 501-508.	0.6	139
114	PET imaging of pulmonary fibrosis. Journal of Nuclear Medicine, 2003, 44, 483-4; author reply 484.	5.0	11
115	Evaluation of 18F-CPFPX, a novel adenosine A1 receptor ligand: in vitro autoradiography and high-resolution small animal PET. Journal of Nuclear Medicine, 2003, 44, 1682-9.	5.0	25
116	Production of the positron emitter 51Mn via the 50Cr(d, n) reaction: targetry and separation of no-carrier-added radiomanganese. Radiochimica Acta, 2002, 90, 167-177.	1.2	9
117	Synthesis and Evaluation of No-Carrier-Added 8-Cyclopentyl-3-(3-[18F]fluoropropyl)-1-propylxanthine ([18F]CPFPX):Â A Potent and Selective A1-Adenosine Receptor Antagonist for in Vivo Imaging. Journal of Medicinal Chemistry, 2002, 45, 5150-5156.	6.4	76
118	Cross Section Measurements on Gas Targets Relevant to the Production of the Positron Emitting Radionuclides14O,18F and76Br. Journal of Nuclear Science and Technology, 2002, 39, 1278-1281.	1.3	7
119	4- 18 F]fluoroarylalkylethers via an improved synthesis of n.c.a. 4- 18 F]fluorophenol. Nuclear Medicine and Biology, 2002, 29, 255-262.	0.6	28
120	Transport of cis- and trans-4-[18F]fluoro-L-proline in F98 glioma cells. Nuclear Medicine and Biology, 2002, 29, 685-692.	0.6	25
121	3-[123I]Iodo-Î±-methyl-L-tyrosine: uptake mechanisms and clinical applications. Nuclear Medicine and Biology, 2002, 29, 625-631.	0.6	69
122	Excitation function of the 18O(p,n)18F nuclear reaction from threshold up to 30 MeV. Radiochimica Acta, 2001, 89, .	1.2	61
123	3-[123I]Iodo-Î±-methyl-L-tyrosine uptake in cerebral gliomas: relationship to histological grading and prognosis. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 855-861.	2.1	33
124	3-[123I]iodo-Î±-methyl-l-tyrosine transport and 4F2 antigen expression in human glioma cells. Nuclear Medicine and Biology, 2001, 28, 5-11.	0.6	12
125	Whole-body kinetics and dosimetry of cis-4-[18F]fluoro-l-proline. Nuclear Medicine and Biology, 2001, 28, 287-292.	0.6	18
126	Alternative syntheses of [73,75Se]selenoethers exemplified for homocysteine[73,75Se]selenolactone. Radiochimica Acta, 2001, 89, 863-866.	1.2	12

#	Article	IF	Citations
127	Direct n.c.a. radioiodination of weakly activated arenes using metal salts. Radiochimica Acta, 2000, 88, 221-228.	1.2	2
128	New modular delivery system for diagnostic and therapeutic pre-targeting using tautomer-specific monoclonal antibody EM-6-47 and 3-substituted adenines. , 1998, 77, 610-619.		3
129	Whole-body kinetics and dosimetry ofl-3-[123I]iodo-?-methyltyrosine. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 1162-1166.	2.1	22
130	Evaluation of radioselenium labeled selenomethionine, a potential tracer for brain protein synthesis by PET. Nuclear Medicine and Biology, 1995, 22, 475-481.	0.6	18
131	Reactivity of iodine monofluoride on sub-micromolar scale with arenes. Tetrahedron Letters, 1994, 35, 9701-9702.	1.4	10
132	Fluoroacylation agents based on small n.c.a. [18F]fluorocarboxylic acids. Applied Radiation and Isotopes, 1994, 45, 715-727.	1.5	80
133	11C-labelling of the analgesic tramadol and its major metabolites by selective O- and N-methylation. International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes, 1992, 43, 1129-1137.	0.5	4
134	Quantification of baboon cortical S2 serotonin receptors in vivo with 3-N-(2â€²-Fl8)fluoroethylspiperone and positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1991, 18, 158-163.	2.1	11
135	Preparation of N.C.A. [17-18F]-fluoroheptadecanoic acid in high yields via aminopolyether supported, nucleophilic fluorination. Journal of Labelled Compounds and Radiopharmaceuticals, 1986, 23, 455-466.	1.0	101
136	Preparation of N.C.A. [18F]-CH2BrF via aminopolyether supported nucleophilic substitution. Journal of Labelled Compounds and Radiopharmaceuticals, 1986, 23, 587-595.	1.0	40
137	Regiospecific no-carrier-added radiobromination and radioiodination of aryltrimethyl Group IVb organometallics. Journal of the Chemical Society Perkin Transactions 1, 1985, , 1941.	0.9	34